<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2023-496</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-8245</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОФТАЛЬМОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPHTHALMOLOGY</subject></subj-group></article-categories><title-group><article-title>Изолированный глазной саркоидоз</article-title><trans-title-group xml:lang="en"><trans-title>Isolated ocular sarcoidosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4601-0904</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафонова</surname><given-names>Т. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Safonova</surname><given-names>Т. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сафонова Татьяна Николаевна, к.м.н., ведущий научный сотрудник отделения патологии слезного аппарата</p><p>119021, Москва, ул. Россолимо, д. 11А, Б</p></bio><bio xml:lang="en"><p>Tatiana N. Safonova, Cand. Sci. (Med.), Leading Researcher at the Department of Pathology of the Lacrimal Apparatus</p><p>11 A, B, Rossolimo St., Moscow, 119021</p></bio><email xlink:type="simple">safotat@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8575-3076</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайцева</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaitseva</surname><given-names>G. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зайцева Галина Валерьевна, к.м.н., научный сотрудник отделения патологии слезного аппарата</p><p>119021, Москва, ул. Россолимо, д. 11А, Б</p></bio><bio xml:lang="en"><p>Galina V. Zaytseva, Cand. Sci. (Med.), Researcher at the Department of Pathology of the Lacrimal Apparatus</p><p>11 A, B, Rossolimo St., Moscow, 119021</p></bio><email xlink:type="simple">privezentseva.galya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт глазных болезней имени М.М. Краснова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnov Research Institute of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>05</month><year>2024</year></pub-date><volume>0</volume><issue>5</issue><fpage>248</fpage><lpage>253</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сафонова Т.Н., Зайцева Г.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Сафонова Т.Н., Зайцева Г.В.</copyright-holder><copyright-holder xml:lang="en">Safonova Т.N., Zaitseva G.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/8245">https://www.med-sovet.pro/jour/article/view/8245</self-uri><abstract><p>Представлено редкое клиническое наблюдение пациентки с изолированным саркоидозом глаз. Саркоидоз – полиэтиологическое заболевание, морфологической особенностью которого является образование эпителиоидно-клеточных гранулем в различных органах и тканях, что сопровождается нарушением их структуры и функции. В патогенез саркоидоза вовлечены как врожденная, так и адаптивная иммунные системы, с поражением лимфоузлов, легких, кожи, органа зрения и т. д. Факторы риска развития саркоидоза окончательно не установлены. Решающую роль в развитии заболевания играют воздействия факторов окружающей среды и генетическая предрасположенность. Приведенное клиническое наблюдение демонстрирует полиморфность клинической картины изолированного глазного саркоидоза. Помимо стандартных офтальмологических методов обследования также был использован генетический метод обратной транскрипции и количественной полимеразной цепной реакции (ОТ-ПЦР, англ. qRT-PCR) для определения профиля экспрессии сигнатурных микроРНК как потенциальных диагностических маркеров саркоидоза органа зрения. Повышение уровня экспрессии hsa-miR-455-3p, hsa-miR-4663, hsamiR6806-3p, hsa-miR-450b-5p, hsa-miR-6716-3p, hsa-miR-5000-5p, hsa-miR150-5p может рассматриваться в качестве потенциального диагностического биомаркера саркоидного поражения структур глаза. При саркоидозе возможно вовлечение слезной железы. В представленном клиническом наблюдении на это указывали результаты функционального обследования, сонографические признаки: выявленные множественные линейные трубчатые гиперэхогенные структуры и снижение скорости кровотока в глазной и слезной артериях, а также увеличение экспрессионной активности hsa-miR150-5p (р &lt; 0,05). С целью профилактики возможного поражения глазной поверхности из-за развития дисфункции слезной железы целесообразно назначение местной слезозамещающей терапии препаратами гиалуроновой кислоты. К числу таких эффективных препаратов можно отнести слезозаменители линейки Оптинол®: Оптинол® Экспресс увлажнение и Оптинол® Глубокое увлажнение.</p></abstract><trans-abstract xml:lang="en"><p>A rare clinical case of a patient with isolated sarcoidosis of the eyes is presented. Sarcoidosis is a polyethological disease, the morphological feature of which is the formation of epithelioid cell granulomas in various organs and tissues, which is accompanied by a violation of their structure and function. Both congenital and adaptive immune systems are involved in the pathogenesis of sarcoidosis, with damage to lymph nodes, lungs, skin, organ of vision, etc. Risk factors for the development of sarcoidosis have not been definitively established. Environmental factors and genetic predisposition play a crucial role in the development of the disease. The above clinical observation demonstrates the polymorphism of the clinical picture of isolated ocular sarcoidosis. In addition to standard ophthalmic examination methods, the genetic method of reverse transcription and quantitative polymerase chain reaction (RT-PCR, English qRT-PCR) was also used to determine the expression profile of signature microRNAs as potential diagnostic markers of sarcoidosis of the organ of <ext-link xlink:href="http://vision.An/" ext-link-type="uri">vision.An </ext-link>increase in the expression level of hsa-miR-455-3p, hsa-miR-4663, hsamiR68063p, hsa-miR-450b-5p, hsa-miR-6716-3p, hsa-miR-5000-5p, hsa-miR150-5p can be considered as potential diagnostic biomarkers of sarcoid lesion of eye structures. With sarcoidosis, the involvement of the lacrimal gland is possible. In the presented clinical observation, this was indicated by the results of a functional examination, sonographic signs: revealed multiple linear tubular hyperechoic structures and a decrease in blood flow velocity in the ocular and lacrimal arteries, as well as an increase in the expression activity of hsa-miR150-5p (p &lt; 0.05). In order to prevent possible damage to the ocular surface due to the development of lacrimal gland dysfunction, it is advisable to prescribe local tear replacement therapy with hyaluronic acid preparations. Such effective drugs include tear substitutes of the Optinol® line: “Optinol® Express Moisture” and “Optinol® Deep Moisture”.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>саркоидная гранулема</kwd><kwd>слезная железа</kwd><kwd>биомаркер</kwd><kwd>микроРНК</kwd><kwd>ОТ-ПЦР</kwd><kwd>препараты искусственной слезы</kwd><kwd>Оптинол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>sarcoid granuloma</kwd><kwd>lacrimal gland</kwd><kwd>biomarker</kwd><kwd>microRNA</kwd><kwd>qRT-PCR</kwd><kwd>artificial tear preparations</kwd><kwd>Optinol</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Madiq B, Taouti H, Ghazza A, Belghmaidi S, Hajji I, Moutaouakil A. Conjunctival lesions. Rev Med Interne. 2021;42(2):140–141. https://doi.org/10.1016/j.revmed.2020.08.020.</mixed-citation><mixed-citation xml:lang="en">Madiq B, Taouti H, Ghazza A, Belghmaidi S, Hajji I, Moutaouakil A. Conjunctival lesions. Rev Med Interne. 2021;42(2):140–141. https://doi.org/10.1016/j.revmed.2020.08.020.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zina S, Khairallah M, Ben Amor H, Ksiaa I, Hadhri R, Attia S et al. Conjunctival granulomas leading to the diagnosis of systemic sarcoidosis. J Fr Ophtalmol. 2022;45(2):e67–e69. https://doi.org/10.1016/j.jfo.2021.06.008.</mixed-citation><mixed-citation xml:lang="en">Zina S, Khairallah M, Ben Amor H, Ksiaa I, Hadhri R, Attia S et al. Conjunctival granulomas leading to the diagnosis of systemic sarcoidosis. J Fr Ophtalmol. 2022;45(2):e67–e69. https://doi.org/10.1016/j.jfo.2021.06.008.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nagata K, Maruyama K, Sugita S, Fukuchi U, Terada Y, Ishizuka A et al. Age differences in sarcoidosis patients with posterior ocular lesions. Ocul Immunol Inflamm. 2014;22(4):257–262. https://doi.org/10.3109/09273948.2013.855796.</mixed-citation><mixed-citation xml:lang="en">Nagata K, Maruyama K, Sugita S, Fukuchi U, Terada Y, Ishizuka A et al. Age differences in sarcoidosis patients with posterior ocular lesions. Ocul Immunol Inflamm. 2014;22(4):257–262. https://doi.org/10.3109/09273948.2013.855796.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160–169. https://doi.org/10.1080/09273940902818861.</mixed-citation><mixed-citation xml:lang="en">Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160–169. https://doi.org/10.1080/09273940902818861.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sève P, Jamilloux Y, Tilikete C, Gerfaud-Valentin M, Kodjikian L, El Jammal T. Ocular Sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):673–688. https://doi.org/10.1055/s-0040-1710536.</mixed-citation><mixed-citation xml:lang="en">Sève P, Jamilloux Y, Tilikete C, Gerfaud-Valentin M, Kodjikian L, El Jammal T. Ocular Sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):673–688. https://doi.org/10.1055/s-0040-1710536.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Эксаренко ОВ, Харлап СИ, Сафонова ТН, Вашкулатова ЭА. Изменение слезной железы при саркоидозе по результатам пространственного ультразвукового цифрового исследования. Вестник офтальмологии. 2013;129(1):10–15. Режим доступа: https://www.mediasphera.ru/issues/vestnik-oftalmologii/2013/1/030042-465X201312.</mixed-citation><mixed-citation xml:lang="en">Eksarenko OV, Kharlap SI, Safonova TN, Vashkulatova EA. Lacrimal gland changes in sarcoidosis according to the results of spatial digital ultrasonography. Vestnik Oftalmologii. 2013;129(1):10–15. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-oftalmologii/2013/1/030042-465X201312.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина АФ. Болезни орбиты. М.: Медицина; 1993. 238 с. Режим доступа: https://rusneb.ru/catalog/010003_000061_b4de67f500a296c62649b2dd6decaf9f/.</mixed-citation><mixed-citation xml:lang="en">Бровкина АФ. Болезни орбиты. М.: Медицина; 1993. 238 с. Режим доступа: https://rusneb.ru/catalog/010003_000061_b4de67f500a296c62649b2dd6decaf9f/.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S, Selva D. Non-infectious Dacryoadenitis. Surv Ophthalmol. 2022;67(2):353–368. https://doi.org/10.1016/j.survophthal.2021.05.011.</mixed-citation><mixed-citation xml:lang="en">Singh S, Selva D. Non-infectious Dacryoadenitis. Surv Ophthalmol. 2022;67(2):353–368. https://doi.org/10.1016/j.survophthal.2021.05.011.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Philip AM, Fernandez-Santos CC, Ramezani K, Dolinko AH, Manhapra A, Look-Why S et al. Ocular Mucus Membrane Pemphigoid: A Primary Versus Secondary Entity. Cornea. 2023;42(3):280–283. https://doi.org/10.1097/ICO.0000000000003056.</mixed-citation><mixed-citation xml:lang="en">Philip AM, Fernandez-Santos CC, Ramezani K, Dolinko AH, Manhapra A, Look-Why S et al. Ocular Mucus Membrane Pemphigoid: A Primary Versus Secondary Entity. Cornea. 2023;42(3):280–283. https://doi.org/10.1097/ICO.0000000000003056.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Седышев СХ, Васильев ВИ. Саркоидоз в практике ревматолога. РМЖ. 2009;(3):156. Режим доступа: https://www.rmj.ru/articles/revmatologiya/Sarkoidoz_v_praktike_revmatologa/.</mixed-citation><mixed-citation xml:lang="en">Sedyshev SH, Vasil’ev V. Sarcoidosis in the practice of a rheumatologist. RMJ. 2009;(3):156. (In Russ.) Available at: https://www.rmj.ru/articles/revmatologiya/Sarkoidoz_v_praktike_revmatologa/.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dal Lago L, Sarrand J, Woff E, Awada A, Vouche M. Sarcoidosis Versus Lymphoma? Eur J Case Rep Intern Med. 2021;8(3):002250. https://doi.org/10.12890/2021_002250.</mixed-citation><mixed-citation xml:lang="en">Dal Lago L, Sarrand J, Woff E, Awada A, Vouche M. Sarcoidosis Versus Lymphoma? Eur J Case Rep Intern Med. 2021;8(3):002250. https://doi.org/10.12890/2021_002250.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Сафонова ТН, Зайцева ГВ, Логинов ВИ, Бурденный АМ, Лукина СС. Взаимосвязь полиморфизмов гена TRIM21 с тяжестью сухого кератоконъюнктивита при ревматоидном артрите и болезни Шегрена. Вестник офтальмологии. 2019;135(5):192–198. Режим доступа: https://www.mediasphera.ru/issues/vestnik-oftalmologii/2019/20010/10042465X2019052192.</mixed-citation><mixed-citation xml:lang="en">Safonova TN, Zaitseva GV, Loginov VI, Burdennyy AM, Lukina SS. Association of polymorphisms of the TRIM21 gene with the severity of dry keratoconjunctivitis in rheumatoid arthritis and Sjogren’s disease. Vestnik Oftalmologii. 2019;135(5):192–198. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-oftalmologii/2019/20010/10042465X2019052192.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Сафонова ТН, Сурнина ЗВ, Зайцева ГВ, Бурденный АМ, Логинов ВИ. Изучение роли полиморфных маркеров rs1478604, rs2292305, rs2228262 гена THBS1 в развитии сухого кератоконъюнктивита при синдроме Шегрена. Бюллетень экспериментальной биологии и медицины. 2020;169(5):640–643. Режим доступа: https://iramn.ru/journals/bbm/2020/5/5045/.</mixed-citation><mixed-citation xml:lang="en">Safonova TN, Surnina ZV, Zaitseva GV, Burdenny AM, Loginov VI. Studying the role of polymorphic markers rs1478604, rs2292305, rs2228262 in THBS1 gene in damaging corneal nerve fibers in autoimmune dry eye syndrome. Bulletin of Experimental Biology and Medicine. 2020;169(5):640–643. (In Russ.) Available at: https://iramn.ru/journals/bbm/2020/5/5045/.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Arger NK, O’Connor B, Koth LL. Molecular profiling in sarcoidosis. Curr Opin Pulm Med. 2020;26(5):562–567. https://doi.org/10.1097/MCP.0000000000000716.</mixed-citation><mixed-citation xml:lang="en">Arger NK, O’Connor B, Koth LL. Molecular profiling in sarcoidosis. Curr Opin Pulm Med. 2020;26(5):562–567. https://doi.org/10.1097/MCP.0000000000000716.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(10):1418–1422. https://doi.org/10.1136/bjophthalmol-2018-313356.</mixed-citation><mixed-citation xml:lang="en">Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(10):1418–1422. https://doi.org/10.1136/bjophthalmol-2018-313356.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ascoli C, Huang Y, Schott C, Turturice BA, Metwally A, Perkins DL, Finn PW. A Circulating MicroRNA Signature Serves as a Diagnostic and Prognostic Indicator in Sarcoidosis. Am J Respir Cell Mol Biol. 2018;58(1):40–54. https://doi.org/10.1165/rcmb.2017-0207OC.</mixed-citation><mixed-citation xml:lang="en">Ascoli C, Huang Y, Schott C, Turturice BA, Metwally A, Perkins DL, Finn PW. A Circulating MicroRNA Signature Serves as a Diagnostic and Prognostic Indicator in Sarcoidosis. Am J Respir Cell Mol Biol. 2018;58(1):40–54. https://doi.org/10.1165/rcmb.2017-0207OC.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Saito S, Keino H, Takasaki I, Abe S, Kohno H, Ichihara K et al. Comparative Analysis of Serum microRNA in Diagnosed Ocular Sarcoidosis versus Idiopathic Uveitis with Ocular Manifestations of Sarcoidosis. Int J Mol Sci. 2022;23(18):10749. https://doi.org/10.3390/ijms231810749.</mixed-citation><mixed-citation xml:lang="en">Saito S, Keino H, Takasaki I, Abe S, Kohno H, Ichihara K et al. Comparative Analysis of Serum microRNA in Diagnosed Ocular Sarcoidosis versus Idiopathic Uveitis with Ocular Manifestations of Sarcoidosis. Int J Mol Sci. 2022;23(18):10749. https://doi.org/10.3390/ijms231810749.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Asakage M, Usui Y, Nezu N, Shimizu H, Tsubota K, Yamakawa N et al. Comprehensive miRNA Analysis Using Serum from Patients with Noninfectious Uveitis. Invest Ophthalmol Vis Sci. 2020;61(11):4. https://doi.org/10.1167/iovs.61.11.4.</mixed-citation><mixed-citation xml:lang="en">Asakage M, Usui Y, Nezu N, Shimizu H, Tsubota K, Yamakawa N et al. Comprehensive miRNA Analysis Using Serum from Patients with Noninfectious Uveitis. Invest Ophthalmol Vis Sci. 2020;61(11):4. https://doi.org/10.1167/iovs.61.11.4.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Liu B, Zhao L, Wei Y, Chen S, Bian L, Guo D et al. MicroRNA expression profile of Lacrimal Glands in rabbit autoimmune dacryoadenitis model. Int J Med Sci. 2020;17(17):2879–2887. https://doi.org/10.7150/ijms.50248.</mixed-citation><mixed-citation xml:lang="en">Liu B, Zhao L, Wei Y, Chen S, Bian L, Guo D et al. MicroRNA expression profile of Lacrimal Glands in rabbit autoimmune dacryoadenitis model. Int J Med Sci. 2020;17(17):2879–2887. https://doi.org/10.7150/ijms.50248.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Сафонова ТН, Харлап СИ, Эксаренко ОВ. Ультразвуковые предикторы формирования синдрома сухого глаза при саркоидозе. Вестник рентгенологии и радиологии. 2019;100(4):186–191. https://doi.org/10.20862/0042-4676-2019-100-4-186-191.</mixed-citation><mixed-citation xml:lang="en">Safonova TN, Kharlap SI, Eksarenko OV. Ultrasonic Predictors of Dry Eye Syndrome in Sarcoidosis. Journal of Radiology and Nuclear Medicine. 2019;100(4):186–191. (In Russ.) https://doi.org/10.20862/0042-4676-2019-100-4-186-191.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011;12(3):325–334. https://doi.org/10.1517/14656566.2010.518612.</mixed-citation><mixed-citation xml:lang="en">Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011;12(3):325–334. https://doi.org/10.1517/14656566.2010.518612.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Бржеский ВВ, Голубев СЮ, Бржеская ИВ, Попов ВЮ. Новые возможности слезозамещающей терапии у больных с синдромом сухого глаза различного генеза. Офтальмология. 2019;16(2):244–251. https://doi.org/10.18008/1816-5095-2019-2-244-251.</mixed-citation><mixed-citation xml:lang="en">Brzheskiy VV, Golubev SYu, Brzheskaja IV, Popov VYu. New Possibilities of Tear Replacement Therapy in Patients with Dry Eye Syndrome of Various Origins. Oftalmologiya. 2019;16(2):244–251. (In Russ.) https://doi.org/10.18008/1816-5095-2019-2-244-251.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Бржеский ВВ, Егорова ГБ, Егоров ЕА. Синдром «сухого глаза» и заболевания глазной поверхности: клиника, диагностика, лечение. М.: ГЭОТАРМедиа; 2016. 464 с. Режим доступа: https://www.geotar.ru/lots/NF0000344.html.</mixed-citation><mixed-citation xml:lang="en">Бржеский ВВ, Егорова ГБ, Егоров ЕА. Синдром «сухого глаза» и заболевания глазной поверхности: клиника, диагностика, лечение. М.: ГЭОТАРМедиа; 2016. 464 с. Режим доступа: https://www.geotar.ru/lots/NF0000344.html.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bischoff G. Drug Report. 2010;4(2):1–12. Available at: https://elojoseco.com/wp-content/uploads/2015/01/Thieme-Drug-Report-2010_A4_en_LR.pdf.</mixed-citation><mixed-citation xml:lang="en">Bischoff G. Drug Report. 2010;4(2):1–12. Available at: https://elojoseco.com/wp-content/uploads/2015/01/Thieme-Drug-Report-2010_A4_en_LR.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lievens C, Berdy G, Douglass D, Montaquila S, Lin H, Simmons P et al. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. Cont Lens Anterior Eye. 2019;42(4):443–449. https://doi.org/10.1016/j.clae.2018.12.003.</mixed-citation><mixed-citation xml:lang="en">Lievens C, Berdy G, Douglass D, Montaquila S, Lin H, Simmons P et al. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. Cont Lens Anterior Eye. 2019;42(4):443–449. https://doi.org/10.1016/j.clae.2018.12.003.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Chiambaretta F, Doan S, Labetoulle M, Rocher N, El Fekih L, Messaoud R et al. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol. 2017;27(1):1–9. https://doi.org/10.5301/ejo.5000836.</mixed-citation><mixed-citation xml:lang="en">Chiambaretta F, Doan S, Labetoulle M, Rocher N, El Fekih L, Messaoud R et al. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol. 2017;27(1):1–9. https://doi.org/10.5301/ejo.5000836.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gomesa JAP, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: A review. Ocul Surf. 2019;17(1):9–19. https://doi.org/10.1016/j.jtos.2018.11.003.</mixed-citation><mixed-citation xml:lang="en">Gomesa JAP, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: A review. Ocul Surf. 2019;17(1):9–19. https://doi.org/10.1016/j.jtos.2018.11.003.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Essaa L, Laughtonb D, Wolffsohn JS. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? Cont Lens Anterior Eye. 2018;41(1):60–68. https://doi.org/10.1016/j.clae.2017.07.007.</mixed-citation><mixed-citation xml:lang="en">Essaa L, Laughtonb D, Wolffsohn JS. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? Cont Lens Anterior Eye. 2018;41(1):60–68. https://doi.org/10.1016/j.clae.2017.07.007.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Бржеский ВВ. Алгоритм выбора слезозаместительной терапии у пациентов в амбулаторной практике. Клиническая офтальмология. 2018;(1):13–19. https://doi.org/10.21689/2311-7729-2018-18-1-13-19.</mixed-citation><mixed-citation xml:lang="en">Brzheskiy VV. Algorithm of selecting the tear replacement therapy in ambulatory practice. Russian Journal of Clinical Ophthalmology. 2018;(1):13–19. (In Russ.) https://doi.org/10.21689/2311-7729-2018-18-1-13-19.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–650. https://doi.org/10.1097/00003226-200310000-00008.</mixed-citation><mixed-citation xml:lang="en">Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–650. https://doi.org/10.1097/00003226-200310000-00008.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Бржеский ВВ, Горбачевская ИН, Голубев СЮ. Новые препараты гиалуроновой кислоты в лечении детей с синдромом сухого глаза. Офтальмология. 2021;18(1):129–135. https://doi.org/10.18008/1816-5095-2021-1-129-135.</mixed-citation><mixed-citation xml:lang="en">Brzheskiy VV, Gorbachevskaya IN, Golubev SY. New Hyaluronic Acid Preparations in the Treatment of Children with Dry Eye Syndrome. Oftalmologiya. 2021;18(1):129–135. (In Russ.) https://doi.org/10.18008/1816-5095-2021-1-129-135.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
